PHARMANUT

PHARMANUT has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €232,934 and a net result of €44,981. Equity is growing by about 42% per year across the filed financial years. Its solvency ranks better than 26% of 39,152 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).